Jain Neha, Kate Anahita, Basu Sayan
The Cornea Institute, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India.
The Cornea Institute, KVC Campus, LV Prasad Eye Institute, Vijayawada, India.
Int J Surg Case Rep. 2022 Aug;97:107409. doi: 10.1016/j.ijscr.2022.107409. Epub 2022 Jul 14.
This report describes a new technique of deep anterior lamellar limbo-keratoplasty for the management of bilateral limbal stem cell deficiency (LSCD) with corneal scarring.
A 45-year-old male presented with chronic sequelae of ocular chemical injury and had bilateral total LSCD with corneal scarring. The visual acuity (VA) in the right eye was counting fingers. A large diameter deep anterior lamellar limbo-keratoplasty (DAL-LK) was carried out and the donor cornea and limbus were sourced from a single tissue. The VA at the last visit, 2.5 years after the surgery was 20/80. A similar presentation was seen in a 31-year-old male with a VA of 20/320 in the right eye. He underwent a DAL-LK and 3 years after the procedure, the VA was 20/60. Both grafts remained clear with no episodes of rejection until the last follow up visit.
Limbal stem cell transplantation with keratoplasty or a keratoprosthesis is required to manage bilateral LSCD with stromal scarring. The former necessitates multiple interventions while the latter is associated with several globe threatening complications. DAL-LK was devised to overcome these disadvantages and offers a simple, single staged technique of simultaneously transplanting the corneal stroma with the limbal stem cells. As the host endothelium is preserved, there is no risk of rejection episodes.
DAL-LK can successfully restore stability of the ocular surface and visually rehabilitate cases with bilateral LSCD and stromal scarring. The procedure has stable long-term outcomes with a good safety profile.
本报告描述了一种用于治疗伴有角膜瘢痕的双侧角膜缘干细胞缺乏(LSCD)的新型深前板层角膜缘移植技术。
一名45岁男性,患有眼部化学伤的慢性后遗症,双侧完全性LSCD并伴有角膜瘢痕。右眼视力为指数。实施了大直径深前板层角膜缘移植术(DAL-LK),供体角膜和角膜缘取自单一组织。术后2.5年最后一次随访时视力为20/80。一名31岁男性也有类似表现,右眼视力为20/320。他接受了DAL-LK手术,术后3年视力为20/60。直到最后一次随访,两块移植片均保持透明,无排斥反应发生。
对于伴有基质瘢痕的双侧LSCD,需要进行角膜缘干细胞移植联合角膜移植术或角膜移植假体植入术。前者需要多次干预,而后者则与多种威胁眼球的并发症相关。设计DAL-LK是为了克服这些缺点,并提供一种简单的单阶段技术,同时移植角膜基质和角膜缘干细胞。由于保留了宿主内皮,因此没有排斥反应的风险。
DAL-LK可以成功恢复眼表稳定性,并使双侧LSCD和基质瘢痕患者获得视觉康复。该手术具有稳定的长期效果和良好的安全性。